Archive for October, 2015

USA300 Methicillin-Resistant Staphylococcus aureus, United States, 2000-2013.

Emerg Infect Dis. 2015 Nov;21(11):1973-80.

Carrel M, Perencevich EN, David MZ.


In the United States, methicillin-resistant Staphylococcus aureus (MRSA) with the USA300 pulsed-field gel electrophoresis type causes most community-associated MRSA infections and is an increasingly common cause of health care-associated MRSA infections.

USA300 probably emerged during the early 1990s. To assess the spatiotemporal diffusion of USA300 MRSA and USA100 MRSA throughout the United States, we systematically reviewed 354 articles for data on 33,543 isolates, of which 8,092 were classified as USA300 and 2,595 as USA100.

Using the biomedical literature as a proxy for USA300 prevalence among genotyped MRSA samples, we found that USA300 was isolated during 2000 in several states, including California, Texas, and midwestern states.

The geographic mean center of USA300 MRSA then shifted eastward from 2000 to 2013. Analyzing genotyping studies enabled us to track the emergence of a new, successful MRSA type in space and time across the country.


October 29, 2015 at 8:22 am

Cloxacillin-susceptible Staphylococcus aureus with high MIC to glycopeptides. Ever we use cloxacillin?

Rev Esp Quimioter. 2015 Sep;28 Suppl 1:25-9.

Article in Spanish

Morales A, Lalueza A, San Juan R, Aguado JM1.

Author information

1José María Aguado, Unidad de Enfermedades Infecciosas. Hospital Universitario 12 de Octubre, Madrid, Spain.


October 29, 2015 at 8:20 am

The Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in England.

Open Forum Infect Dis. 2015 Mar 12;2(2):ofv035.


Duerden B1, Fry C2, Johnson AP3, Wilcox MH4.

Author information

1Cardiff University Medical School , Heath Park , United Kingdom.

2Department of Health, Richmond House, London , United Kingdom.

3Department of Healthcare-Associated Infections and Antimicrobial Resistance , Centre for Infectious Disease Surveillance and Control , Public Health England , London , United Kingdom.

4Leeds Teaching Hospitals, University of Leeds and Public Health England , United Kingdom.


October 29, 2015 at 8:19 am

Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Antimicrob Agents Chemother. 2015 Apr;59(4):2102-12.

Akins RL1, Katz BD2, Monahan C2, Alexander D2.

Author information

1Methodist Charlton Medical Center, Dallas, Texas, USA Louisiana State University Health Sciences Center-Shreveport, School of Medicine, Shreveport, Louisiana, USA

2Cubist Pharmaceuticals, Lexington, Massachusetts, USA.


October 28, 2015 at 12:45 pm

Ceftaroline fosamil: A super-cephalosporin?

Cleve Clin J Med. 2015 Jul;82(7):437-44.

Ghamrawi RJ1, Neuner E2, Rehm SJ3,4.

Author information

1Clinical Pharmacist Specialist, Adult Antimicrobial Stewardship Department of Pharmacy, University Hospitals Case Medical Center, Cleveland, OH, USA.

2Infectious Diseases Clinical Specialist, Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA. E-mail:

3Department of Infectious Disease, Cleveland Clinic, Cleveland, OH, USA.

4Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.


Ceftaroline is a broad-spectrum cephalosporin used to treat infections caused by a variety of microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae.

However, it is not active against Pseudomonas aeruginosa, Bacteroides fragilis, and carbapenem-resistant Enterobacteriaceae.

Its approved indications include community-acquired bacterial pneumonia and bacterial infections of skin and skin structures.

It has also been used off-label to treat osteomyelitis, endocarditis, and meningitis caused by ceftaroline-susceptible organisms.


October 26, 2015 at 9:41 pm

Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options.

BMC Infect Dis. 2015 Aug 5;15:313.

Golan Y1.

Author information

1Tufts Medical Center, Department of Medicine, Division of Geographic Medicine and Infectious Disease, 800 Washington St, Boston, MA, 02446, USA.



Empiric therapy for healthcare-associated infections remains challenging, especially with the continued development of Gram-negative organisms producing extended-spectrum β-lactamases (ESBLs) and the threat of multi-drug-resistant organisms. Current treatment options for resistant Gram-negative infections include carbapenems, tigecycline, piperacillin-tazobactam, cefepime, ceftazidime, and two recently approved therapies, ceftolozane-tazobactam and ceftazidime-avibactam.


This systematic literature review surveys the published clinical trial evidence available since 2000 in support of both current and emerging treatment options in the settings of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI). When available, clinical cure rates for patients with infections from ESBL-producing strains are provided, as is information about efficacy against Pseudomonas aeruginosa.


Clinical trial evidence to guide selection of empiric antibiotic therapy in patients with complicated, hospital-acquired, Gram-negative IAIs and UTIs is limited. Though most of the clinical trials explored in this overview enrolled patients with complicated infections, often patients with severe infections and multiple comorbidities were excluded.


Practitioners in the clinical setting who are treating patients with complicated, hospital-acquired, Gram-negative IAIs and UTIs need to consider the possibility of polymicrobial infections, antibiotic-resistant organisms, and/or severely ill patients with multiple comorbidities. There is a severe shortage of evidence-based research to guide the selection of empiric antibiotic therapy for many patients in this setting. New therapies recently approved or in late-stage development promise to expand the number of options available for empiric therapy of these hospital-acquired, Gram-negative infections.


October 26, 2015 at 9:37 pm

Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999–2012

Emerging Infectious Diseases NOV 2015 V.21 N.11


Latania K. Logan, John P. Renschler, Sumanth Gandra, Robert A. Weinstein, Ramanan Laxminarayan, and for the Centers for Disease Control Prevention Epicenters Program

Rush University Medical Center, Chicago, Illinois, USA (L.K. Logan, R.A. Weinstein); John H. Stroger, Jr. Hospital of Cook County, Chicago (L.K. Logan, R.A. Weinstein); Center for Disease Dynamics, Economics and Policy, Washington, DC, USA (J.P. Renschler, S. Gandra, R. Laxminarayan); Public Health Foundation of India, New Delhi, India (R. Laxminarayan); Princeton University, Princeton, New Jersey, USA (R. Laxminarayan)

The prevalence of carbapenem-resistant Enterobacteriaceae (CRE) infections is increasing in the United States. However, few studies have addressed their epidemiology in children.

To phenotypically identify CRE isolates cultured from patients 1–17 years of age, we used antimicrobial susceptibilities of Enterobacteriaceae reported to 300 laboratories participating in The Surveillance Network–USA database during January 1999–July 2012.

Of 316,253 isolates analyzed, 266 (0.08%) were identified as CRE. CRE infection rate increases were highest for Enterobacter species, blood culture isolates, and isolates from intensive care units, increasing from 0.0% in 1999–2000 to 5.2%, 4.5%, and 3.2%, respectively, in 2011–2012.

CRE occurrence in children is increasing but remains low and is less common than that for extended-spectrum β-lactamase–producing Enterobacteriaceae.

The molecular characterization of CRE isolates from children and clinical epidemiology of infection are essential for development of effective prevention strategies.


October 26, 2015 at 8:35 am

Older Posts Newer Posts


October 2015

Posts by Month

Posts by Category